Pressmeddelande -
Scandinavian Biopharma recruits Christin Hindrika Strid as Clinical Operations Manager
Scandinavian Biopharma strengthens the organization in Clinical Operations through the recruitment of the pharmacist Christin Hindrika Strid, as Clinical Operations Manager. The company is in a late-stage clinical development phase and has an ambitious clinical development programme with several ongoing clinical studies for the ETEC vaccine candidate ETVAX®. Together with Anna Hill, Christin will be responsible for ensuring that the ongoing and future clinical trials are carried out according to the highest quality standards and in a cost-effective manner. Christin has extensive experience from similar positions at various pharmaceutical companies such as Moberg Pharma, Boehringer Ingelheim, SBL Vaccin and Bayer.
Initially Christin will focus on the ETVAX® paediatric trial programme in Africa.
– I feel very excited to be part of the development of this ETEC-vaccine. Preliminary data from the study in Zambia is showing promising immunogenicity results and confirm the favorable safety profile of the vaccine. The analyses of all the participants’ tests are now virtually done, and I am looking forward with excitement towards the first half of 2021 when the results are expected to be completed, says Christin Hindrika Strid.
–Christin’s experience and competence will suit us well and I am pleased to welcome her to our team. The fact that Christin has previously worked with clinical vaccine studies exactly within this niche field will be very valuable for us, says Björn Sjöstrand, CEO of Scandinavian Biopharma.
Ämnen
Kategorier
About Scandinavian Biopharma
Scandinavian Biopharma is a research-based specialty biopharma company determined to give people all over the world a longer and better life. Together with researchers at the University of Gothenburg and the international non-profit organization PATH, Scandinavian Biopharma is developing the first vaccine against ETEC which causes diarrhoea in both travellers and endemic populations.
The development project is mainly funded by the EDCTP programme, which is supported under Horizon 2020, the European Union’s (EU) Framework Programme for Research and Innovation, as well as by PATH and the U.S. Army (USAMRAA).
Scandinavian Biopharma also acts as a distributor for a wide range of specialty biopharma products in Europe with a focus on vaccines and immunoglobulins.
About ETEC
Enterotoxigenic Escherichia coli, or ETEC, is a major cause of bacterial diarrhoeal disease.
ETEC infections are particularly common in low- and middle-income countries (LMIC). In children younger than 5 years, it has been estimated that 1.7 billion episodes of diarrhoea occur annually. ETEC represents a major cause of these episodes and accounts for approximately 400 000 deaths among children living in LMICs. In addition, diarrhoea is associated with an increased risk of stunting (i.e.impaired growth and development). Stunting affects cognitive development which might determine a child’s ability to learn, their educational attainment, and future earnings and it also puts children at risk due to other severe infectious diseases.
ETEC is also the leading cause of travellers’ diarrhoea, affecting more than 35 million travellers every year.
About ETVAX®
To date, no vaccine against ETEC exists and ETVAX® is the only ETEC vaccine candidate in late-stage development. The strong immunogenicity and safety data, as well as the promising field efficacy data, clearly distinguish ETVAX® as the lead vaccine candidate against ETEC. Successful development of this vaccine will address a huge unmet medical need for children in LMICs as well as for travellers.
